Symposium

How Low Can You Go? Targeting of Deep Remission in the Management of Crohn’s Disease

Launch Date
10/27/2024 at 06:00 am EST
Credit Amount
1.5
Credit Expires
10/27/2024

Faculty

Bruce E. Sands, MD, MS
Moderator
Dr. Burrill B. Crohn Professor of Medicine
Chief, Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY
Marita Kametas, MSN, APN, FNP-BC, CMSRN, COCN
Inflammatory Bowel Disease Advanced Practice Nurse
Manager of Gastroenterology Advanced Practice Provider Services
The University of Chicago Medicine
Chicago, IL
Millie D. Long, MD, MPH
Professor of Medicine 
Vice-Chief for Education
Director, Gastroenterology and Hepatology Fellowship Program
Division of Gastroenterology and Hepatology 
University of North Carolina 
Chapel Hill, NC 
Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration

Statement of Need

Crohn’s disease (CD) can cause progressive bowel damage, impaired quality of life, and permanent disability. Severity and presentation can vary widely from person to person, necessitating an individualized treatment approach. The use of more readily available imaging modalities such as intestinal ultrasound and magnetic resonance enterography can be added to standard monitoring practices to improve disease management. Additionally, targeting deeper remission at a histological level is an emerging treatment target for patients with CD. Clinicians in collaboration with a multidisciplinary care team must become knowledgeable on individualized care and novel imaging modalities to optimize treatment for patients with CD.

In this CME Outfitters live symposium, expert faculty will guide learners on how to integrate knowledge of the heterogeneity of CD in severity and manifestation into patient assessment and treatment. Learners will be instructed on utilizing alternative diagnostic and evaluation tools beyond colonoscopy for evaluating symptoms in patients with CD. Faculty will model incorporation of histopathologic treatment targets as an objective measure of inflammation in CD to inform clinical decision-making.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Integrate knowledge of the heterogeneity of CD in severity and manifestation into patient assessment and treatment
  • Utilize alternative diagnostic and evaluation tools beyond colonoscopy for evaluating symptoms in patients with CD
  • Incorporate histopathologic treatment targets as an objective measure of inflammation in CD to inform clinical decision-making

Financial Support

This activity is supported by an educational grant from Lilly.

Target Audience

U.S. and international gastroenterologists, and gastroenterology nurse practitioners (NPs) and physician associates (PAs) (with the exception of HCPs in the United Kingdom)

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.5

CME Outfitters, LLC, designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.5

This activity is designated for 1.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Interprofessional (IPCE) 1.5

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.

Physician Assistants (AAPA): 1.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid unitl 12/27/2024. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Sands reports the following financial relationships:

Consultant: Abbvie Inc.; Amgen Inc.; AstraZeneca; Boehringer-Ingelheim; Bristol Myers Squibb Company; Celltrion Inc.; Lilly; Galapagos; Genentech, Inc.; Gilead Sciences, Inc.; GSK; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; and Ventyx Biosciences, Inc.

Research Support: Bristol Myers Squibb and Janssen Pharmaceuticals, Inc.

Stock Shareholder (directly purchased): Ventyx Biosciences, Inc.

Other financial or material support: Editorial support from AbbVie Inc., Bristol Myers Squibb Company, Celltrion Inc., Lilly, Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer Inc., and Takeda Pharmaceuticals U.S.A., Inc.

Ms. Kametas reports the following financial relationships:

Advisory Board: Lilly and Pfizer Inc.

Consultant: TKG Therapeutics, Inc.

Grants: GI Research Foundation

Speakers Bureau: Abbvie Inc.; Janssen. Pharmaceuticals, Inc.; and Pfizer Inc.

Dr. Long reports the following financial relationships:

Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Target RWE

Research Support: Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

The following individuals have no financial relationships to disclose: 

Jeffrey Helfand, DO (Peer Reviewer)
Elizabeth Naber, MSN, RN, CCRN-K, CNRN, TCRN (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Kasey Brandt, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff  (Planning Committee)

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

MM-147-102724-11

How Low Can You Go? Targeting of Deep Remission in the Management of Crohn’s Disease
Event Date: 10/27/2024 at 06:00 am EST
Register